Intrathecal Chemotherapy in Burkitt's Lymphoma

Meningeal involvement with Burkitt lymphoma cells constitutes the most challenging therapeutic problem in the management of Burkitt's tumour. The results of intrathecal chemotherapy with methotrexate or cytosine arabinoside in 55 episodes of malignant pleocytosis in 38 patients with Burkitt...

Full description

Saved in:
Bibliographic Details
Published in:BMJ 1971-08, Vol.3 (5773), p.508-512
Main Authors: Ziegler, J. L., Bluming, A. Z.
Format: Article
Language:English
Subjects:
Adolescent
Burkitt lymphoma
Burkitt Lymphoma - cerebrospinal fluid
Burkitt Lymphoma - drug therapy
Cerebrospinal Fluid - cytology
Chemotherapy
Child
Child, Preschool
Cytarabine - administration & dosage
Disease remission
Dosage
Hospital admissions
Humans
Injections, Spinal
Leukocytosis
Medical treatment
Methotrexate - administration & dosage
Neoplasia
Papers and Originals
Relapse
Subarachnoid space
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b4228-2a59557121922e231a0681397d114f7715d7b002ece2e514c98c5e335f6ab9d43
cites
container_end_page 512
container_issue 5773
container_start_page 508
container_title BMJ
container_volume 3
creator Ziegler, J. L.
Bluming, A. Z.
description Meningeal involvement with Burkitt lymphoma cells constitutes the most challenging therapeutic problem in the management of Burkitt's tumour. The results of intrathecal chemotherapy with methotrexate or cytosine arabinoside in 55 episodes of malignant pleocytosis in 38 patients with Burkitt's tumour are described. The response was complete in nearly all patients after the administration of either agent. Cerebrospinal fluid (C.S.F.) remissions were more prolonged in patients receiving intrathecal methotrexate or cytosine arabinoside daily for four days as opposed to a 10-day schedule. A controlled randomized trial of “prophylactic” intrathecal chemotherapy in patients without malignant cells in the C.S.F. on admission showed no protective effect against the subsequent development of malignant pleocytosis. Future therapeutic approaches are considered in the light of these results.
doi_str_mv 10.1136/bmj.3.5773.508
format article
fullrecord <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1800463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>25415656</jstor_id><sourcerecordid>25415656</sourcerecordid><originalsourceid>FETCH-LOGICAL-b4228-2a59557121922e231a0681397d114f7715d7b002ece2e514c98c5e335f6ab9d43</originalsourceid><addsrcrecordid>eNqFUU1rGzEUFKElNWmuuQUMhZYcdqOn770UWpO2AZPk0IbcHtq1HK-zu3Kl3VL_-2ixcZteepH0mNEw84aQM6A5AFeXZbvOeS61Tgc1R2QCQplMGs5fkQmlVGcghH5DTmNcp5FxbQoljsmxBFoIgAnJr7s-2H7lKttMZyvX-vQOdrOd1t308xCe6r7_EKfzbbtZ-da-Ja-XtonudH-fkB9frr7PvmXz26_Xs0_zrBSMmYxZWUipgUHBmGMcLFUGeKEXAGKpNciFLpMfVznmJIiqMJV0nMulsmWxEPyEfNzpboaydYvKjS4b3IS6tWGL3tb4EunqFT76XwiGUqF4Eni_Fwj-5-Bij20dK9c0tnN-iKi5FCKtJBHf_UNc-yF0KRyC1ooWhoNJrHzHqoKPMbjlwQpQHKvAVAVyHKvAVEX6cP53gAN9v_g_-Dr2PhxgJgVIJVXCsx1ex979PuA2PKHSXEu8uZ-h0A_A6PwOxxgXO_7o4z_engGP56eh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776098318</pqid></control><display><type>article</type><title>Intrathecal Chemotherapy in Burkitt's Lymphoma</title><source>BMJ</source><source>PubMed Central</source><creator>Ziegler, J. L. ; Bluming, A. Z.</creator><creatorcontrib>Ziegler, J. L. ; Bluming, A. Z.</creatorcontrib><description>Meningeal involvement with Burkitt lymphoma cells constitutes the most challenging therapeutic problem in the management of Burkitt's tumour. The results of intrathecal chemotherapy with methotrexate or cytosine arabinoside in 55 episodes of malignant pleocytosis in 38 patients with Burkitt's tumour are described. The response was complete in nearly all patients after the administration of either agent. Cerebrospinal fluid (C.S.F.) remissions were more prolonged in patients receiving intrathecal methotrexate or cytosine arabinoside daily for four days as opposed to a 10-day schedule. A controlled randomized trial of “prophylactic” intrathecal chemotherapy in patients without malignant cells in the C.S.F. on admission showed no protective effect against the subsequent development of malignant pleocytosis. Future therapeutic approaches are considered in the light of these results.</description><identifier>ISSN: 0007-1447</identifier><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1468-5833</identifier><identifier>DOI: 10.1136/bmj.3.5773.508</identifier><identifier>PMID: 5109411</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Adolescent ; Burkitt lymphoma ; Burkitt Lymphoma - cerebrospinal fluid ; Burkitt Lymphoma - drug therapy ; Cerebrospinal Fluid - cytology ; Chemotherapy ; Child ; Child, Preschool ; Cytarabine - administration &amp; dosage ; Disease remission ; Dosage ; Hospital admissions ; Humans ; Injections, Spinal ; Leukocytosis ; Medical treatment ; Methotrexate - administration &amp; dosage ; Neoplasia ; Papers and Originals ; Relapse ; Subarachnoid space</subject><ispartof>BMJ, 1971-08, Vol.3 (5773), p.508-512</ispartof><rights>Copyright 1971 British Medical Journal</rights><rights>Copyright BMJ Publishing Group LTD Aug 28, 1971</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b4228-2a59557121922e231a0681397d114f7715d7b002ece2e514c98c5e335f6ab9d43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800463/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800463/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,3181,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/5109411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ziegler, J. L.</creatorcontrib><creatorcontrib>Bluming, A. Z.</creatorcontrib><title>Intrathecal Chemotherapy in Burkitt's Lymphoma</title><title>BMJ</title><addtitle>Br Med J</addtitle><description>Meningeal involvement with Burkitt lymphoma cells constitutes the most challenging therapeutic problem in the management of Burkitt's tumour. The results of intrathecal chemotherapy with methotrexate or cytosine arabinoside in 55 episodes of malignant pleocytosis in 38 patients with Burkitt's tumour are described. The response was complete in nearly all patients after the administration of either agent. Cerebrospinal fluid (C.S.F.) remissions were more prolonged in patients receiving intrathecal methotrexate or cytosine arabinoside daily for four days as opposed to a 10-day schedule. A controlled randomized trial of “prophylactic” intrathecal chemotherapy in patients without malignant cells in the C.S.F. on admission showed no protective effect against the subsequent development of malignant pleocytosis. Future therapeutic approaches are considered in the light of these results.</description><subject>Adolescent</subject><subject>Burkitt lymphoma</subject><subject>Burkitt Lymphoma - cerebrospinal fluid</subject><subject>Burkitt Lymphoma - drug therapy</subject><subject>Cerebrospinal Fluid - cytology</subject><subject>Chemotherapy</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cytarabine - administration &amp; dosage</subject><subject>Disease remission</subject><subject>Dosage</subject><subject>Hospital admissions</subject><subject>Humans</subject><subject>Injections, Spinal</subject><subject>Leukocytosis</subject><subject>Medical treatment</subject><subject>Methotrexate - administration &amp; dosage</subject><subject>Neoplasia</subject><subject>Papers and Originals</subject><subject>Relapse</subject><subject>Subarachnoid space</subject><issn>0007-1447</issn><issn>0959-8138</issn><issn>1468-5833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1971</creationdate><recordtype>article</recordtype><recordid>eNqFUU1rGzEUFKElNWmuuQUMhZYcdqOn770UWpO2AZPk0IbcHtq1HK-zu3Kl3VL_-2ixcZteepH0mNEw84aQM6A5AFeXZbvOeS61Tgc1R2QCQplMGs5fkQmlVGcghH5DTmNcp5FxbQoljsmxBFoIgAnJr7s-2H7lKttMZyvX-vQOdrOd1t308xCe6r7_EKfzbbtZ-da-Ja-XtonudH-fkB9frr7PvmXz26_Xs0_zrBSMmYxZWUipgUHBmGMcLFUGeKEXAGKpNciFLpMfVznmJIiqMJV0nMulsmWxEPyEfNzpboaydYvKjS4b3IS6tWGL3tb4EunqFT76XwiGUqF4Eni_Fwj-5-Bij20dK9c0tnN-iKi5FCKtJBHf_UNc-yF0KRyC1ooWhoNJrHzHqoKPMbjlwQpQHKvAVAVyHKvAVEX6cP53gAN9v_g_-Dr2PhxgJgVIJVXCsx1ex979PuA2PKHSXEu8uZ-h0A_A6PwOxxgXO_7o4z_engGP56eh</recordid><startdate>19710828</startdate><enddate>19710828</enddate><creator>Ziegler, J. L.</creator><creator>Bluming, A. Z.</creator><general>British Medical Journal Publishing Group</general><general>British Medical Association</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19710828</creationdate><title>Intrathecal Chemotherapy in Burkitt's Lymphoma</title><author>Ziegler, J. L. ; Bluming, A. Z.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b4228-2a59557121922e231a0681397d114f7715d7b002ece2e514c98c5e335f6ab9d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1971</creationdate><topic>Adolescent</topic><topic>Burkitt lymphoma</topic><topic>Burkitt Lymphoma - cerebrospinal fluid</topic><topic>Burkitt Lymphoma - drug therapy</topic><topic>Cerebrospinal Fluid - cytology</topic><topic>Chemotherapy</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cytarabine - administration &amp; dosage</topic><topic>Disease remission</topic><topic>Dosage</topic><topic>Hospital admissions</topic><topic>Humans</topic><topic>Injections, Spinal</topic><topic>Leukocytosis</topic><topic>Medical treatment</topic><topic>Methotrexate - administration &amp; dosage</topic><topic>Neoplasia</topic><topic>Papers and Originals</topic><topic>Relapse</topic><topic>Subarachnoid space</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ziegler, J. L.</creatorcontrib><creatorcontrib>Bluming, A. Z.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ziegler, J. L.</au><au>Bluming, A. Z.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intrathecal Chemotherapy in Burkitt's Lymphoma</atitle><jtitle>BMJ</jtitle><addtitle>Br Med J</addtitle><date>1971-08-28</date><risdate>1971</risdate><volume>3</volume><issue>5773</issue><spage>508</spage><epage>512</epage><pages>508-512</pages><issn>0007-1447</issn><issn>0959-8138</issn><eissn>1468-5833</eissn><abstract>Meningeal involvement with Burkitt lymphoma cells constitutes the most challenging therapeutic problem in the management of Burkitt's tumour. The results of intrathecal chemotherapy with methotrexate or cytosine arabinoside in 55 episodes of malignant pleocytosis in 38 patients with Burkitt's tumour are described. The response was complete in nearly all patients after the administration of either agent. Cerebrospinal fluid (C.S.F.) remissions were more prolonged in patients receiving intrathecal methotrexate or cytosine arabinoside daily for four days as opposed to a 10-day schedule. A controlled randomized trial of “prophylactic” intrathecal chemotherapy in patients without malignant cells in the C.S.F. on admission showed no protective effect against the subsequent development of malignant pleocytosis. Future therapeutic approaches are considered in the light of these results.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>5109411</pmid><doi>10.1136/bmj.3.5773.508</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1447
ispartof BMJ, 1971-08, Vol.3 (5773), p.508-512
issn 0007-1447
0959-8138
1468-5833
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1800463
source BMJ; PubMed Central
subjects Adolescent
Burkitt lymphoma
Burkitt Lymphoma - cerebrospinal fluid
Burkitt Lymphoma - drug therapy
Cerebrospinal Fluid - cytology
Chemotherapy
Child
Child, Preschool
Cytarabine - administration & dosage
Disease remission
Dosage
Hospital admissions
Humans
Injections, Spinal
Leukocytosis
Medical treatment
Methotrexate - administration & dosage
Neoplasia
Papers and Originals
Relapse
Subarachnoid space
title Intrathecal Chemotherapy in Burkitt's Lymphoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T18%3A20%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intrathecal%20Chemotherapy%20in%20Burkitt's%20Lymphoma&rft.jtitle=BMJ&rft.au=Ziegler,%20J.%20L.&rft.date=1971-08-28&rft.volume=3&rft.issue=5773&rft.spage=508&rft.epage=512&rft.pages=508-512&rft.issn=0007-1447&rft.eissn=1468-5833&rft_id=info:doi/10.1136/bmj.3.5773.508&rft_dat=%3Cjstor_pubme%3E25415656%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b4228-2a59557121922e231a0681397d114f7715d7b002ece2e514c98c5e335f6ab9d43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1776098318&rft_id=info:pmid/5109411&rft_jstor_id=25415656&rfr_iscdi=true